CTS implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
Seasonal monitoring of epidemic triggers for West Nile Virus (WNV) NAT tested donations will begin J...
The revised CTS algorithm associated with the Ortho platform is now available for review. Clie...
On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
On Wednesday August 15, 2018 at 11:00AM PDT, we will be hosting a webinar regarding the changes to F...
CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The ...